Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_assertion type Assertion NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_head.
- NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_assertion description "[When adding CD56 or CD7 labeling to the Ogata score, sensitivity rose to 66% for low-risk myelodysplastic syndromes, to 89% for myelodysplastic/myeloproliferative neoplasms and to 97% for refractory anemia with excess of blasts.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_provenance.
- NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_assertion evidence source_evidence_literature NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_provenance.
- NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_assertion SIO_000772 25637056 NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_provenance.
- NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_assertion wasDerivedFrom befree-2016 NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_provenance.
- NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_assertion wasGeneratedBy ECO_0000203 NP1259701.RA74b8AAtF2LC_JB6RoPHwuuG4bwfzbR-U9HEAQwnWIXI130_provenance.